Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 5/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827038 | 0.88 | NPC1 (0.58) | GRM4TRPV1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1829494 | 0.82 | TRPV1 (0.60) | TRPV1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL27656468 | 0.81 | TRPV1 (0.66) | TRPV1NPC1RAB9AMAPTPTPN1 | |
| SCHEMBL28172197 | 0.80 | TLR7 (0.71) | GRM4TRPV1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2785436 | 0.80 | TRPV1 (0.47) | GRM4TRPV1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8297618 | 0.80 | NPC1 (0.59) | GRM4TRPV1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5964783 | 0.79 | ALDH1A1 (0.51) | TRPV1NPC1RAB9AMAPT | |
| SCHEMBL1828384 | 0.79 | TRPV1 (0.60) | TRPV1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL1826907 | 0.79 | S1PR1 (0.50) | TRPV1NPC1 | |
| SCHEMBL30904868 | 0.77 | GRM4 (0.60) | GRM4NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2319516-A1 | Compounds for treating inflammatory and autoimmune disorders | Synta Pharmaceuticals Corp. (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2319516-A1 | Compounds for treating inflammatory and autoimmune disorders | Synta Pharmaceuticals Corp. (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-1651232-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | GRM4 3582/4885TRPV1 795/4885NPC1 142/4885 |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | GRM4 3582/4885TRPV1 795/4885NPC1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.